We hope you are all excited as we are and we are really looking forward to finally seeing you face-to-face this weekend at the #eau22 conference in Amsterdam!
Urologists at Heatherwood Hospital have introduced an outpatient therapy for bladder cancer, enabling patients to be treated closer to home.
Synergo is a treatment for non-muscle invasive bladder cancer that hasn't responded to BCG immunotherapy.
Read more https://t.co/VjzCvRxEZV
News of the clinical potential of #Synergo has reached the other side of the world. Strategies to Get Drugs across Bladder Penetrating Barriers for Improving Bladder Cancer Therapy https://t.co/CHM7Ind9TT via @MDPIOpenAccess@Wang11051@kingshaohua
Hot off the press! Thrilled to share this new article!
Long-term Experience with #Synergo. 299 pts, 72.9% HR according #EAU. Brummelhuis, I.S.G. et al. Radboud University Medical Center on Cancers 2021. https://t.co/d0Hk3Ue6qX
#BladderCancer#blcsm#thermochemotherapy
Hot off the press! Thrilled to share this new article!
Long-term Experience with #Synergo. 299 pts, 72.9% HR according #EAU. Brummelhuis, I.S.G. et al. Radboud University Medical Center on Cancers 2021. https://t.co/d0Hk3Ue6qX
#BladderCancer#blcsm#thermochemotherapy
In vitro using #Synergo presented by Dr. Brummelhuis. RF inhibits the cell proliferation of NMIBC cells at 37°C and when combined with HT and/or chemotherapeutic agents. Benign cells were not affected by RF.
https://t.co/GXOFc1kdGp
#research#CancerResearch
#NMIBC is considered a chronic disease by many physicians.
Early diagnosis, close follow-ups are just as important as effective treatments. https://t.co/LYNIJRd57Q
We wish to congratulate Dr. Miriam Heibeler - with Head of department Prof. Oliver Reich @muenchenklinik
Harlaching @LMU_Uniklinikum München for her comprehensive study on #Synergo® for #NMIBC
https://t.co/uruRfyDYQo
#thermochemotherapy#BCGUnresponsive